On Mar. 10, 2020, ImmunityBio announced results from studies evaluating N-803, an IL-15 superagonist, alone and in combination with anti-HIV broadly neutralizing antibodies (bNAbs), in SHIV-infected, antiretroviral therapy-suppressed rhesus macaques (RM). The data provided evidence that repeated co-dosing of N-803 in combination with bNABs may facilitate long-term viral remission in the absence of antiretroviral therapy.